Suppliers & Vendors
Traditional promotion efforts, including details and sampling, can only affect about 10% of prescriptions, an IMS study found, suggesting that the bulk of promotion dollars is misplaced.
If you still haven't entered the MM&M Awards 2009, then you'd better move fast--today (June 5) is the final deadline for submissions.
The Coalition for Healthcare Communication said it doesn't oppose ACCME's proposal to set up an independent entity for disbursal of CME funding - provided that it's not the only game in town and CME providers don't have to pay for it.
A pair of American Medical Association committee reports urges that industry-funded CME be put on a tighter leash, but they're a far cry from the ban on commercial support called for by the AMA's Council on Ethical and Judicial Affairs a year ago.
Marketers anticipate substantial cuts in DTC spend in 2009, according to a Cegedim Dendrite survey in which 58% of respondents said they'd cut consumer ad spend this year. Last year 28% said they'd cut back on consumer advertising.
In an effort to improve lab practices in the field of assisted reproduction technology (ART), Cook Medical launched a microsite and video lab tour.
Physicians and medical institutions should shun gifts, reps, samples and ghostwriting, said the Institute of Medicine's conflict of interest committee in its full recommendations.
The Accreditation Council for Continuing Medical Education is considering offering an accreditation flagging CME as being free of drug and device industry support -- a kind of Good Housekeeping Seal for CME.
IMS Health and SDI are seeking a Supreme Court review of an appeals court ruling that restricts the commercial use of prescriber data in the state of New Hampshire.
Iowa's state Senate passed a healthcare bill containing some of the toughest restrictions on drug company contacts with physicians yet.
An influential advisory board urged Congress to impose far-reaching transparency rules on payments to healthcare professionals and organizations interacting with the drug industry--including reporting samples, in part to aid counterdetailing efforts.
The cuts keep coming. AstraZeneca will make another 6,000 job cuts for a total of 15,000, or 23% of its global workforce of 65,000, by 2013, and Sepracor is slashing its sales force.
Drug industry watchdog The Prescription Project called on FDA to take action against video news releases and B-roll for Abbott, Medtronic and Stryker medical devices appearing on YouTube, and said the agency should issue guidance for online ads.
A federal appeals court has overturned a lower court's injunction of New Hampshire's ban on commercial provision of prescription data, arguing that such restrictions do not constitute an abridgment of free speech.
Education and innovation were they keys to this year's MM&M Awards in the consumer marketing and advertising categories as the judges rewarded brains over mere branding.
A new training effort aims to help medical education faculty distinguish between certified and promotional CME.
Reps. John Dingell and Bart Stupak (both D-MI) wrote the FDA to question its use of a pharma PR firm in developing a website about DTC advertising for consumers.
Identifying physicians who drive the new-to-brand market in a given category — prior to developing a marketing strategy - allows marketers to save time and money by avoiding docs with tin ears.
A snap survey of physicians found a yearning for smarter sales reps who know their disease states back and forth and can use clinical studies in their details.
Merck announced a strategic partnership with inVentiv Health, whereby Merck will utilize inVentiv's contract sales staff to supplement Merck's in-house sales force.
As ACCME's public comment period on a proposed restructuring of the CME funding structure drew to a close, industry groups blasted the accrediting body for what they see as an overreaction imperiling medical education.
Total commercial support of accredited CME scarcely budged in 2007, rising 1% to $1.2 billion, while the share of commercial support going to publishing and education companies declined 4.2% to $594 million, according to the ACCME's annual report.
Verispan has been bought by rival healthcare analytics firm SDI for an undisclosed price.
The judges' scores are in for the MM&M Awards 2008 submissions and the shortlist of finalists in each category will be revealed simultaneously in News Brief and at mmm-online.com next Tuesday, July 22.
Contract sales firm PDI has announced the retirement of its CEO Michael Marquard.
Ogilvy Healthworld has announced the following promotions and additions to its medical education division. Ellen McCarthy was promoted to senior scientific associate from scientific associate. Michelle Goldblum moved up to account executive from assistant account executive.
Stiefel Laboratories announced two senior staff promotions.
Form true partnerships with your clients, keep them happy and make your recommendations short and sweet — that's the message from pharmaceutical companies to their marketing research suppliers and consultants, according to a new study by marketRx, a Cognizant Company.
Gilead Sciences appointed John Toole, MD, PhD, to the position of SVP, corporate development.
Cephalon has contracted inVentiv Selling Solutions, a division of inVentiv Health, to provide sales support for its muscle relaxant Amrix.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.